Blueprint Medicines (BPMC) Tops Q2 EPS by 49c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Blueprint Medicines (BPMC) PT Raised to $155 at Stifel
August 1, 2024 12:14 PM EDTStifel analyst Bradley Canino raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $155.00 (from $150.00) while maintaining a Buy rating.
The analyst comments "A 13% Ayvakit beat and 11% increase to the FY24 Ayvakit guidance midpoint is fundamentally positive, but for today at least... More
